Streetbeat News

Products Services

JAGX

Jaguar Health, Inc. (NASDAQ:JAGX) has entered into a revenue sharing license and commercialization agreement with Quadri Pharmaceuticals Store LLC. The agreement grants Quadri Pharma exclusive rights to promote, commercialize, and distribute a powder formulation of crofelemer for rare intestinal failure diseases in multiple Middle East countries, following regulatory approval. Quadri Pharma will cover 50% of the development costs for the specified rare disease indications for three years.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:50 pm

GOOGL

MSFT

QCOM

SSNLF

Samsung Electronics Co Ltd. plans to introduce generative AI technology to its Galaxy smartphones, starting with the Galaxy S24. The technology will allow AI-related tasks to be performed directly on the smartphone without an internet connection. The Galaxy S24 might use Qualcomm Inc.'s Snapdragon 8 Gen 3 chipset, which has AI-specific features. It's unclear if Samsung will use Microsoft Corp.-backed OpenAI's ChatGPT or a different solution.

Portfolio Pulse from Rounak Jain

November 02, 2023 | 12:33 pm

BWAY

BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced that the Clinical TMS Society (CTMSS) has published the first coverage recommendations for smoking addiction treatment using transcranial magnetic stimulation (TMS). BrainsWay's Deep TMS is the only TMS technology to have received FDA clearance for the treatment of smoking addiction. The CTMSS now recommends TMS coverage for individuals with a confirmed diagnosis of Tobacco Use Disorder (TUD) who failed two alternative treatment methods, cannot tolerate drugs, or have other comorbid medical conditions.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:31 pm

AUID

International fintech provider Bieases has chosen authID Inc. (NASDAQ:AUID) to secure its digital wallet. The partnership will see the launch of authID's biometric authentication platform to prevent identity fraud and account takeover. Bieases operates in the US, UK, and EU, offering financial services and payments through its digital wallet. The authID platform will provide strong identity verification and document authentication for online onboarding, binding the verified identity to the Bieases digital wallet.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:29 pm

BRAG

MGM

Bragg Gaming Group has launched its new content and Remote Game Server (RGS) technology with BetMGM in New Jersey. The content rollout is powered by Bragg's new RGS technology with BetMGM. Bragg also provides iGaming content for BetMGM players in Michigan and Pennsylvania. The interactive casino market in New Jersey is expected to generate $1.8 billion in Gross Win in 2023.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:29 pm

TEVA

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new data supporting the safety, efficacy, and real-world effectiveness of AUSTEDO tablets for treating Huntington's disease (HD) chorea. The data will be presented at the Huntington Study Group® (HSG) Annual Meeting. The results show that 92% of patients achieved optimal dosing by week 12 with the AUSTEDO 4-week patient titration kit. The data also reinforce the efficacy and tolerability of AUSTEDO.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:28 pm

TNXP

Tonix Pharmaceuticals' vaccine candidate, TNX-1800, has been selected by the National Institute of Allergy and Infectious Diseases (NIAID) for inclusion in early phase clinical trials. The trials are part of the Project NextGen initiative, aimed at developing the next generation of vaccines and therapeutics for COVID-19. The Phase 1 clinical trial of TNX-1800 is expected to start in the second half of 2024, with NIAID covering the full cost of the trial. Tonix will supply the vaccine candidate.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:26 pm

WKSP

Worksport Ltd. (NASDAQ:WKSP) is preparing for an alpha release of its COR battery system. The company is streamlining its supply chain and has formed partnerships with global suppliers. The initial release will serve as a preliminary user iteration before its mass-market release in North America. Worksport is also expanding its production capabilities in response to increasing demand. The company's subsidiary, Terravis Energy, plans to increase research and development for its heat pump.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:25 pm

RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has received a reimbursement recommendation from the Canadian Agency for Drugs and Technologies in Health (CADTH) for its drug IMCIVREE (setmelanotide), used for weight management in patients with obesity due to Bardet-Biedl syndrome (BBS). The recommendation is based on the demonstrated clinical benefit in a Phase 3 trial. IMCIVREE is the first and only therapy approved in Canada for this purpose.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:24 pm

CRBP

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) presented results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The studies demonstrated robust pre-clinical anti-tumor activity of CRB-601, alone and in combination with anti-PD-1 therapy. The company plans to submit an Investigational New Drug application for CRB-601 by the end of 2023 and expects to initiate its Phase 1 study by the end of June 2024.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:23 pm